Cryptic determinant of a4b7 binding in the v2 loop of hiv-1 gp120

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tassaneetrithep, Boonrat ^a,b   Tivon, Doreen ^c   Swetnam, James ^c,e   Karasavvas, Nicos ^d   Michael, Nelson L ^b   Kim, Jerome H ^b   Marovich, Mary ^b   Cardozo, Timothy ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d U S ARMY   (United States)

^e GOOGLE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN RECEPTOR; GLYCOPROTEIN GP 120; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRIN; INTEGRIN ALPHA4BETA7; PROTEIN BINDING; VIRUS ANTIGEN;

ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; VIRUS CELL INTERACTION; VIRUS STRAIN; AMINO ACID SEQUENCE; CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIGENS, VIRAL; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INTEGRINS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL LOAD;

EID: 84907482263     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108446     Document Type: Article

References (21)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286
3. Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, et al. (2013) Analysis of V2 antibody responses induced in vaccinees in the ALVAC/ AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 8: e53629
4. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420
5. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: 301-309
6. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, et al. (2012) Transmitted/ founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 8: e1002686
7. Brenchley JM, Price DA, Douek DC (2006) HIV disease: fallout from a mucosal catastrophe? Nat Immunol 7: 235-239
8. Ansari AA, Reimann KA, Mayne AE, Takahashi Y, Stephenson ST, et al. (2011) Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 186: 1044-1059
9. Jelicic K, Cimbro R, Nawaz F, Huang da W, Zheng X, et al. (2013) The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol 14: 1256-1265
10. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, et al. (2012) The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 28: 1444-1457
11. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, et al. (2014) Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6: 228-238
12. Abagyan R, Totrov M (1994) Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 235: 983-1002
13. Almond D, Cardozo T (2010) Assessment of immunologically relevant dynamic tertiary structural features of the HIV-1 V3 loop crown R2 sequence by ab initio folding. J Vis Exp
14. Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, et al. (2010) Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 26: 717-723
15. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477-1483
16. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343
17. Zolla-Pazner S, Cardozo T (2010) Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 10: 527-535
18. Arnautova YA, Abagyan RA, Totrov M (2011) Development of a new physicsbased internal coordinate mechanics force field and its application to protein loop modeling. Proteins 79: 477-498
19. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, et al. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176-186
20. Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, et al. (2013) The frequency of alpha(4)beta(7)(high) memory CD4(+) T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr 64: 325-331
21. Korber BT, Foley BT, Kuiken CL, Pillai SK, Sodroski JG (1998) Numbering positions in HIV relative to HXB2CG. Los Alamos, NM: Los Alamos National Laboratory